人类生物检体市场规模、份额和成长分析：检体类型、应用、最终用途、储存类型、采购类型、地区和产业预测，2026-2033年

2024年全球人类生物检体市场价值为46亿美元，预计将从2025年的50亿美元成长到2033年的97.5亿美元。预测期（2026-2033年）的复合年增长率预计为8.7%。

全球人类生物检体市场涵盖组织、血液、细胞和DNA等生物材料的采集、处理、储存和分发，这些材料对于研发、诊断和治疗开发至关重要。转化研究和精准医疗的需求不断增长，对高品质、带註释的样本的需求也随之增加，这有助于加速药物发现和改善患者分层。该市场正从区域生物样本库转向互联互通的资料库，凸显了整合临床数据和样本的重要性。对可互通资料库和知情同意平台的投入不断增加，促进了医院和国家生物样本库之间的合作。此外，区块链技术增强了可追溯性，提供了不可篡改的检体来源记录，提高了样本的可发现性和提供者的可信度，同时简化了分散市场中的监管合规流程。

全球人类生物检体市场驱动因素

对生物标记发现和转化研究的日益重视显着增加了对高品质、高註释的人体组织和体液检体的需求，从而扩大了样本采集、处理和储存服务的市场。研究机构和行业相关人员正在寻求各种疾病特异性样本，用于检验研究对象和评估生物标记的有效性。为了应对这一不断增长的需求，生物样本库和商业供应商正在提升服务水准并建立伙伴关係。同时，用于制定标准化通讯协定、改善知情同意流程和简化物流的投资也大幅增加，所有这些都在建立一个强大且永续的生态系统，并推动市场持续成长。

全球人类生物检体市场的限制因素

全球人类生物检体市场面临许多製约因素，包括法规结构的差异、不同的知情同意要求以及关于样本进出口和再利用的不统一指导方针。这造成了复杂的合规环境，阻碍了市场发展。各机构在寻求跨国合作和将生物样本衍生产品商业化时面临法律上的模糊地带，导致筹资策略保守，并限制了关键材料的共用。此外，管理各种伦理核准和资料保护条例的需求增加了行政负担，延长了计划週期，并阻碍了部分相关人员与外部样本提供者的合作，最终抑制了市场的成长潜力。

全球人类生物检体市场趋势

全球人类生物检体市场正日益受到整合生物样本库网路兴起的影响。这些网路促进了不同机构间更紧密的合作，推动了高效的样本共用、标准化的通讯协定以及对各种样本库的更便捷存取。透过强调互通性和统一的知情同意框架，这些网络有效地减少了重复工作，扩大了研究人群，并促进了多中心合作研究，从而加速了转化研究的进程。此外，平台和实验室资讯系统（LIS）的整合，以及标准化的元资料收集，显着提高了检体的可追溯性和品质保证。这种合作框架为学术机构、临床机构和商业机构之间建立可扩展的伙伴关係关係奠定了基础，最终推动了全球诊断、治疗方法和精准医疗的发展。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

市场考察

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场吸引力指数
• PESTEL 分析
• 监理情势

全球人类生物检体市场规模：按检体类型和复合年增长率划分（2026-2033 年）

• 组织检体
• 生物液体
• 细胞材料
• 核酸

全球人类生物检体市场规模：按应用和复合年增长率划分（2026-2033 年）

• 癌症研究
• 药物发现
• 诊断
  • 生物标记发现
• 转化研究
  • 基因组研究
• 精准医疗
• 感染疾病研究
  • COVID-19
  • HIV
  • 结核
• 神经系统和心血管系统检查

全球人类生物检体市场规模：依最终用途和复合年增长率划分（2026-2033 年）

• 製药公司
• 生技公司
• CRO（受託研究机构）
• 学术机构
• 医院和生物样本库
• 诊断检查室
• 政府机构
• 非营利组织

全球人类生物检体市场规模：按储存类型和复合年增长率划分（2026-2033 年）

• 冷藏
  • -80°C 或液态氮(LN2)
  • 低温储存
  • 液态氮（-196 度C）
• 室温保存
• 福马林固定与保存

全球人类生物检体市场规模：依采购类型和复合年增长率划分（2026-2033 年）

• 正向收集
• 过去的检体

全球人类生物检体市场规模：按地区和复合年增长率划分（2026-2033 年）

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 2023-2025年营收年比比较

主要企业简介

• BioIVT
• Precision for Medicine
• Conversant Bio
• Indivumed GmbH
• REPROCELL Inc.
• US Biolab Corporation, Inc.
• Biobank Graz
• ProteoGenex Inc.
• Seracare Life Sciences
• Celdara Medical
• Coriell Institute for Medical Research
• HudsonAlpha Institute for Biotechnology
• LabCorp
• Bionano Genomics
• Mayo Clinic Biobank
• Viacyte
• QIAGEN
• Asterand Bioscience
• Global Bioclinical
• Omnigenics

结论与建议

Global Human Biospecimens Market size was valued at USD 4.6 Billion in 2024 and is poised to grow from USD 5.0 Billion in 2025 to USD 9.75 Billion by 2033, growing at a CAGR of 8.7% during the forecast period (2026-2033).

The global human biospecimens market involves the collection, processing, storage, and distribution of biological materials, including tissues, blood, cells, and DNA, essential for research, diagnostics, and therapy development. The growing need for high-quality annotated specimens is propelled by the demands of translational research and precision medicine, facilitating drug discovery and improving patient stratification. This market is transitioning from local biobanks to interconnected repositories, emphasizing the importance of integrating clinical data with specimens. Investments in interoperable databases and consent platforms are on the rise, fostering collaborations among hospitals and national biobanks. Additionally, blockchain technology can enhance traceability, providing an immutable record of specimen provenance, thereby improving discoverability and donor trust while streamlining regulatory compliance in a fragmented market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Biospecimens market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Human Biospecimens Market Segments Analysis

Global human biospecimens market is segmented by specimen type, application, end use, storage type, procurement type and region. Based on specimen type, the market is segmented into Tissue Specimens, Biofluids, Cellular Material and Nucleic Acids. Based on application, the market is segmented into Cancer Research, Drug Discovery, Diagnostics, Translational Research, Precision Medicine, Infectious Disease Studies and Neurology and Cardiovascular Research. Based on end use, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Institutes, Hospitals and Biobanks, Diagnostic Laboratories, Government Organizations and Non-Profit Organizations. Based on storage type, the market is segmented into Cold Storage, Ambient Storage and Formalin-Fixed Storage. Based on procurement type, the market is segmented into Prospective Collection and Retrospective Samples. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Human Biospecimens Market

The growing emphasis on biomarker discovery and translational research has significantly increased the demand for high-quality, well-annotated human tissue and fluid specimens, thus broadening the market for collection, processing, and storage services. Research organizations and industry stakeholders are seeking diverse, disease-specific samples to validate research targets and evaluate biomarker efficacy. This heightened demand has prompted biobanks and commercial suppliers to enhance their services and forge partnerships. In response, there has been a surge in investment aimed at developing standardized protocols, refining consent processes, and improving logistics, all of which contribute to a robust and sustainable ecosystem that drives continued market expansion.

Restraints in the Global Human Biospecimens Market

The Global Human Biospecimens market faces considerable constraints due to a patchwork of regulatory frameworks, differing consent mandates, and uneven guidelines for the import, export, and reuse of samples. This creates a complex compliance landscape that hampers market development. Organizations encounter legal ambiguities when pursuing cross-border partnerships or commercializing products derived from biospecimens, resulting in conservative procurement strategies and restricted sharing of critical materials. Additionally, the necessity to manage varied ethical approvals and data protection regulations adds to administrative burdens, prolonging project timelines and deterring some stakeholders from collaborating with external sample providers, ultimately stalling the market's growth potential.

Market Trends of the Global Human Biospecimens Market

The Global Human Biospecimens market is increasingly influenced by the emergence of integrated biobank networks, which facilitate enhanced collaboration among various institutions. These networks promote streamlined sample sharing, standardized protocols, and improved access to a diverse range of specimen repositories. By emphasizing interoperability and unified consent frameworks, they effectively minimize duplication, broaden research cohorts, and encourage multi-center studies that expedite translational research. Furthermore, the integration of platforms with laboratory information systems and standardized metadata capture significantly boosts specimen traceability and quality assurance. This collaborative framework paves the way for scalable partnerships among academic, clinical, and commercial entities, ultimately advancing the development of diagnostics, therapeutics, and precision medicine globally.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Human Biospecimens Market Size by Specimen Type & CAGR (2026-2033)

• Market Overview
• Tissue Specimens
• Biofluids
• Cellular Material
• Nucleic Acids

Global Human Biospecimens Market Size by Application & CAGR (2026-2033)

• Market Overview
• Cancer Research
• Drug Discovery
• Diagnostics
  • Biomarker Discovery
• Translational Research
  • Genomic Research
• Precision Medicine
• Infectious Disease Studies
  • COVID-19
  • HIV
  • TB
• Neurology and Cardiovascular Research

Global Human Biospecimens Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations
• Academic Institutes
• Hospitals and Biobanks
• Diagnostic Laboratories
• Government Organizations
• Non-Profit Organizations

Global Human Biospecimens Market Size by Storage Type & CAGR (2026-2033)

• Market Overview
• Cold Storage
  • -80°C or LN2
  • Cryogenic
  • Liquid Nitrogen (-196°C)
• Ambient Storage
• Formalin-Fixed Storage

Global Human Biospecimens Market Size by Procurement Type & CAGR (2026-2033)

• Market Overview
• Prospective Collection
• Retrospective Samples

Global Human Biospecimens Market Size & CAGR (2026-2033)

• North America (Specimen Type, Application, End Use, Storage Type, Procurement Type)
  • US
  • Canada
• Europe (Specimen Type, Application, End Use, Storage Type, Procurement Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Specimen Type, Application, End Use, Storage Type, Procurement Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Specimen Type, Application, End Use, Storage Type, Procurement Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Specimen Type, Application, End Use, Storage Type, Procurement Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• BioIVT
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision for Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Conversant Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indivumed GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REPROCELL Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• US Biolab Corporation, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biobank Graz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ProteoGenex Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seracare Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celdara Medical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coriell Institute for Medical Research
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HudsonAlpha Institute for Biotechnology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LabCorp
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bionano Genomics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayo Clinic Biobank
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viacyte
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asterand Bioscience
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Bioclinical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omnigenics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations